ATE385810T1 - Verwendung von dna oder rna zur herstellung eines medikaments zur behandlung von tumoren - Google Patents

Verwendung von dna oder rna zur herstellung eines medikaments zur behandlung von tumoren

Info

Publication number
ATE385810T1
ATE385810T1 AT02075756T AT02075756T ATE385810T1 AT E385810 T1 ATE385810 T1 AT E385810T1 AT 02075756 T AT02075756 T AT 02075756T AT 02075756 T AT02075756 T AT 02075756T AT E385810 T1 ATE385810 T1 AT E385810T1
Authority
AT
Austria
Prior art keywords
proteins
medication
rna
dna
produce
Prior art date
Application number
AT02075756T
Other languages
English (en)
Inventor
Elizabeth G Nabel
Gary J Nabel
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27110984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE385810(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE385810T1 publication Critical patent/ATE385810T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A61B2017/22084—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance stone- or thrombus-dissolving
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
AT02075756T 1991-06-28 1992-06-26 Verwendung von dna oder rna zur herstellung eines medikaments zur behandlung von tumoren ATE385810T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72450991A 1991-06-28 1991-06-28
US07/741,244 US5328470A (en) 1989-03-31 1991-07-26 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor

Publications (1)

Publication Number Publication Date
ATE385810T1 true ATE385810T1 (de) 2008-03-15

Family

ID=27110984

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02075756T ATE385810T1 (de) 1991-06-28 1992-06-26 Verwendung von dna oder rna zur herstellung eines medikaments zur behandlung von tumoren
AT92914172T ATE214576T1 (de) 1991-06-28 1992-06-26 Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92914172T ATE214576T1 (de) 1991-06-28 1992-06-26 Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür

Country Status (9)

Country Link
US (1) US5328470A (de)
EP (4) EP1213032B1 (de)
JP (3) JP3712409B2 (de)
AT (2) ATE385810T1 (de)
CA (1) CA2112376A1 (de)
DE (2) DE69232497T2 (de)
DK (1) DK0591385T3 (de)
ES (1) ES2301602T3 (de)
WO (1) WO1993000051A1 (de)

Families Citing this family (620)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5575815A (en) * 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5843089A (en) * 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US6743623B2 (en) * 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
US5586982A (en) * 1992-04-10 1996-12-24 Abela; George S. Cell transfection apparatus and method
US6936025B1 (en) 1992-05-19 2005-08-30 Bacchus Vascular, Inc. Thrombolysis device
US5713848A (en) 1993-05-19 1998-02-03 Dubrul; Will R. Vibrating catheter
US6806084B1 (en) * 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
CA2148934C (en) * 1992-11-09 2005-08-02 French W. Anderson Targetable vector particles
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
DE69331526T2 (de) * 1992-11-18 2002-10-24 Arch Development Corp., Chicago Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
US5658565A (en) * 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5830461A (en) * 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
US5658780A (en) * 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
ATE221575T1 (de) * 1993-05-10 2002-08-15 Univ Michigan Gentransfer zu den pankreatischen epithelzellen
WO1994027612A1 (en) * 1993-05-20 1994-12-08 Baylor College Of Medicine Genetic therapy for cardiovascular disease
JPH09500013A (ja) * 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
WO1995003843A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US6682728B1 (en) * 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
ES2077519B1 (es) * 1993-11-22 1996-07-01 Fernandez De Lomana Euge Anaya Cateter intraaortico para perfusion y conservacion renal.
US5792106A (en) * 1993-12-02 1998-08-11 Scimed Life Systems, Inc. In situ stent forming catheter
US5409012A (en) * 1993-12-30 1995-04-25 Boston Scientific Corporation Sample collection using catheter with expandable member
NZ278765A (en) 1993-12-30 1998-05-27 Harvard College Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use
DE4411402A1 (de) * 1994-03-31 1995-10-05 Juergen Schrader DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
WO1995027494A1 (en) * 1994-04-11 1995-10-19 Sloan-Kettering Institute For Cancer Research DEFECTIVE HERPES AND DEFECTIVE ADENO-ASSOCIATED VIRUS VECTORS WITH p53 FOR THE TREATMENT OF CANCER
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
JPH10509696A (ja) * 1994-10-12 1998-09-22 フォーカル， インコーポレイテッド 生分解性ポリマーを介する標的化送達
US5713861A (en) * 1994-10-17 1998-02-03 Vanarthos; William Trauma urethral catheter and method of using same
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
DE59507224D1 (de) * 1994-12-28 1999-12-16 Max Delbrueck Centrum Neues cholesterolderivat für den liposomalen gentransfer
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU4740096A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Direct administration of gene delivery vehicles at multiple sites
US6630455B1 (en) 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6100242A (en) * 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US6210356B1 (en) 1998-08-05 2001-04-03 Ekos Corporation Ultrasound assembly for use with a catheter
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US6531455B1 (en) * 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US5837693A (en) * 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5922687A (en) * 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5766901A (en) * 1995-05-04 1998-06-16 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for delivering a nucleotide into cell nuclei
US6322548B1 (en) 1995-05-10 2001-11-27 Eclipse Surgical Technologies Delivery catheter system for heart chamber
ES2187648T3 (es) * 1995-05-16 2003-06-16 Karl Tryggvason Metodo para la administracion de farmacos para terapia genica.
US6638264B1 (en) * 1995-05-16 2003-10-28 Biostratum Incorporation Perfusion apparatus and methods for pharmaceutical delivery
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US5674198A (en) * 1995-06-23 1997-10-07 Cordis Corporation Tandem balloon catheter
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US5725568A (en) * 1995-06-27 1998-03-10 Scimed Life Systems, Inc. Method and device for recanalizing and grafting arteries
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
ATE309000T1 (de) * 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
CN101028523A (zh) * 1995-11-30 2007-09-05 德克萨斯州立大学董事会 诊断和治疗肿瘤的方法及组合物
JP2000502682A (ja) * 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US5998384A (en) * 1996-01-26 1999-12-07 Hisamitsu Pharmaceutical Co., Inc. Endoscopic administration of an HSV-tk gene to treat digestive organ cancer
US6077834A (en) * 1996-02-09 2000-06-20 Cheng; Pi-Wan Receptor ligand-facilitated delivery of biologically active molecules
DE69733815T2 (de) 1996-02-15 2006-06-08 Biosense Webster, Inc., Diamond Bar Sonde zur exkavation
US6037332A (en) * 1996-02-20 2000-03-14 Emory University Method of urinary bladder instillation
US5866340A (en) * 1996-03-22 1999-02-02 Johns Hopkins University Selective expression of desired genes in cells expressing oncoproteins
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
DE19620687A1 (de) * 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
AU2437397A (en) 1996-07-17 1998-02-09 Medtronic, Inc. System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
DE69736862T2 (de) * 1996-07-17 2007-05-31 Medtronic, Inc., Minneapolis Abgabesystem zur Abgabe von genetischem Material an Herzgewebe
US6443974B1 (en) * 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5868719A (en) * 1997-01-15 1999-02-09 Boston Scientific Corporation Drug delivery balloon catheter device
US6494861B1 (en) 1997-01-15 2002-12-17 Boston Scientific Corporation Drug delivery system
JP2001510365A (ja) * 1997-02-04 2001-07-31 クック ウロロジカル インク． 恥骨上ドレナージカテーテル
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
AU737727B2 (en) * 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
DE69842225D1 (de) 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
US6001069A (en) * 1997-05-01 1999-12-14 Ekos Corporation Ultrasound catheter for providing a therapeutic effect to a vessel of a body
US6676626B1 (en) * 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US6723063B1 (en) * 1998-06-29 2004-04-20 Ekos Corporation Sheath for use with an ultrasound element
US6582392B1 (en) * 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
DE19726244C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme und Rutosid zur Vorbeugung bzw. Behandlung der Transplantatabstoßung
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
DE19729769A1 (de) 1997-07-11 1999-01-14 Cardiogene Gentherapeutische S Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
US6177272B1 (en) * 1997-07-21 2001-01-23 The Regents Of The University Of Michigan Method for treating vascular proliferative diseases with p27 and fusions thereof
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
AU1114699A (en) * 1997-10-24 1999-05-17 Children's Medical Center Corporation Methods for promoting cell transfection (in vivo)
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6251418B1 (en) * 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US6197324B1 (en) 1997-12-18 2001-03-06 C. R. Bard, Inc. System and methods for local delivery of an agent
US6794369B2 (en) 1997-12-31 2004-09-21 Pharmasonics Methods, systems, and kits for intravascular nucleic acid delivery
US6699231B1 (en) 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US6372498B2 (en) * 1997-12-31 2002-04-16 Pharmasonics, Inc. Methods, systems, and kits for intravascular nucleic acid delivery
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
US20020061522A1 (en) 2000-02-29 2002-05-23 Glucksmann Maria Alexandra 1983, 52881, 2398, 45449, 50289, and 52872 novel G protein-coupled receptors and uses therefor
US6148222A (en) * 1998-07-10 2000-11-14 Cardiocommand, Inc. Esophageal catheters and method of use
US7700353B2 (en) * 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
AU5518499A (en) * 1998-08-26 2000-03-21 Bavarian Nordic Research Institute A/S Guanylate binding protein (gbp-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
US6312402B1 (en) 1998-09-24 2001-11-06 Ekos Corporation Ultrasound catheter for improving blood flow to the heart
US6689121B1 (en) 1998-09-24 2004-02-10 C. R. Bard, Inc. Systems and methods for treating ischemia
US6135976A (en) * 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US6251079B1 (en) 1998-09-30 2001-06-26 C. R. Bard, Inc. Transthoracic drug delivery device
US20060205034A1 (en) * 1998-10-30 2006-09-14 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
EP1140278B1 (de) * 1998-12-14 2004-05-19 Tre Esse Progettazione Biomedica S.r.l Kathetersystem zur durchführung einer intramyokardialen therapeutischen behandlung
US7122019B1 (en) 2000-11-28 2006-10-17 Flowmedica Inc. Intra-aortic renal drug delivery catheter
US6749598B1 (en) * 1999-01-11 2004-06-15 Flowmedica, Inc. Apparatus and methods for treating congestive heart disease
US7329236B2 (en) * 1999-01-11 2008-02-12 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US7780628B1 (en) 1999-01-11 2010-08-24 Angiodynamics, Inc. Apparatus and methods for treating congestive heart disease
US6695830B2 (en) * 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
WO2000061184A2 (en) * 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
US6224566B1 (en) 1999-05-04 2001-05-01 Cardiodyne, Inc. Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
WO2000067825A1 (en) 1999-05-07 2000-11-16 Microheart, Inc. Apparatus and method for delivering therapeutic and diagnostic agents
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040229779A1 (en) * 1999-05-14 2004-11-18 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US8778899B2 (en) * 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6774120B1 (en) * 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6641553B1 (en) 1999-06-02 2003-11-04 Boston Scientific Corporation Devices and methods for delivering a drug
US7147633B2 (en) * 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7001766B2 (en) * 1999-07-20 2006-02-21 Curagen Corporation Nucleic acid sequences encoding human angiopoietin-like polypeptides
US6475744B1 (en) 1999-07-22 2002-11-05 The General Hospital Corporation Methods for identifying compounds which modulate circadian rhythm
WO2001006989A2 (en) * 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6855160B1 (en) 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
PL203128B1 (pl) * 1999-09-09 2009-08-31 Univ California Liposom zawierający taksan i zastosowanie liposomu kationowego
PT1220830E (pt) * 1999-09-24 2007-06-11 Proteon Therapeutics Inc Utilização de elastase para abertura de artérias e veias obstruídas
US6855806B1 (en) * 1999-10-15 2005-02-15 Curagen Corporation Thymosin beta 10-like proteins and nucleic acids encoding same
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US8808272B2 (en) * 1999-10-28 2014-08-19 Boston Scientific Scimed, Inc. Biocompatible medical devices
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US8168178B2 (en) * 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CN100460874C (zh) 2000-02-29 2009-02-11 阿尔康公司 筛检卷曲相关蛋白激动剂或拮抗剂的方法
WO2001066747A2 (en) * 2000-03-03 2001-09-13 Curagen Corporation Proteins named fctrx and nucleic acids encoding same
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7517352B2 (en) 2000-04-07 2009-04-14 Bacchus Vascular, Inc. Devices for percutaneous remote endarterectomy
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001081408A2 (en) 2000-04-21 2001-11-01 New England Medical Center G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
DK1287364T3 (da) 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
US20040005554A1 (en) * 2000-05-08 2004-01-08 Tayar Nabil El Novel glycoproteins and methods of use thereof
US20030219786A1 (en) * 2000-08-11 2003-11-27 Applied Research Systems Ars Holding N.V. Novel glycoproteins and methods of use thereof
US7232421B1 (en) 2000-05-12 2007-06-19 C. R. Bard, Inc. Agent delivery systems
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20040034193A1 (en) * 2001-06-13 2004-02-19 Samy Ashkar Biosynthetic oncolytic molecules and uses therefor
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
US20040023259A1 (en) * 2000-07-26 2004-02-05 Luca Rastelli Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2417982A1 (en) * 2000-08-03 2002-02-14 The University Of Utah Research Foundation Manipulation of arterial-venous identity
AU2001286584A1 (en) * 2000-08-18 2002-03-04 Massachusetts Institute Of Technology Inhibition of protein-protein interaction
US7651696B2 (en) * 2000-08-25 2010-01-26 Nexeon Medical Systems, Inc. Implantable device for treating disease states and methods of using same
US6740331B1 (en) * 2000-08-25 2004-05-25 Global Gene Therapies, Inc. Apparatus for the delivery of drugs or gene therapy into a patient's vasculature and methods of use
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2422215A1 (en) * 2000-09-20 2002-03-28 Amgen Inc. B7-like molecules and uses thereof
ES2338757T3 (es) 2000-10-18 2010-05-12 The Brigham And Women's Hospital, Inc. Polipeptidos ligandos para selectina-e/selectina-l de la celula hematopoyetica y metodos de utilizacion de los mismos.
NZ526617A (en) 2000-11-28 2004-09-24 Wyeth Corp Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
JP2004526425A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7015012B2 (en) * 2001-02-09 2006-03-21 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
EP1372708B1 (de) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
EP2388590A1 (de) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
US20030148298A1 (en) * 2001-04-03 2003-08-07 O''toole Margot Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
US20030017159A1 (en) * 2001-05-02 2003-01-23 Jerome Ritz Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
US7244853B2 (en) * 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
BR0210283A (pt) * 2001-06-07 2004-09-14 Wyeth Corp Receptor acoplado à proteìna-g e usos para o mesmo
ATE347695T1 (de) 2001-06-07 2006-12-15 Chemocentryx Inc Zellwanderungsassay
US20030152947A1 (en) * 2001-06-15 2003-08-14 Crossman David C. Methods for detecting and treating the early onset of aging-related conditions
US20040236377A1 (en) * 2001-07-02 2004-11-25 Medtronic, Inc. System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
US20040029790A1 (en) * 2001-07-05 2004-02-12 Meera Patturajan Novel human proteins, polynucleotides encoding them and methods of using the same
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030129613A1 (en) * 2001-07-05 2003-07-10 Fernandes Elma R. Novel human proteins and polynucleotides encoding them
BR0211111A (pt) 2001-07-12 2004-06-22 Univ Massachusetts Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula
EP1900815B1 (de) 2001-07-12 2016-09-07 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
US20040030096A1 (en) * 2001-08-02 2004-02-12 Linda Gorman Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002323217B2 (en) 2001-08-15 2008-04-10 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
US20070082337A1 (en) * 2004-01-27 2007-04-12 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US6808518B2 (en) * 2001-09-28 2004-10-26 Ethicon, Inc. Methods and devices for treating diseased blood vessels
AU2002340063B2 (en) 2001-09-28 2007-05-10 Brigham Young University Novel cyclooxygenase variants and methods of use
JP2005503820A (ja) * 2001-10-01 2005-02-10 ブラッドリー・エイチ・ストラウス 完全動脈閉塞においてガイドワイヤーの通過を容易にするコラゲナーゼの使用
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030199442A1 (en) * 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US7745418B2 (en) * 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
US7220239B2 (en) 2001-12-03 2007-05-22 Ekos Corporation Catheter with multiple ultrasound radiating members
AU2002353016A1 (en) * 2001-12-03 2003-06-17 Ekos Corporation Small vessel ultrasound catheter
US7141044B2 (en) 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
EP1455815A4 (de) 2001-12-19 2006-11-02 Millennium Pharm Inc Mitglieder der familie der humanen diacylglycerol-acyltransferase 2 (dgat2) und ihre verwendung
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US6939374B2 (en) * 2001-12-21 2005-09-06 Scimed Life Systems, Inc. Stents, stenting systems, and related methods for agent delivery
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
AU2003212481A1 (en) * 2002-02-28 2003-09-09 Ekos Corporation Ultrasound assembly for use with a catheter
US7153685B2 (en) * 2002-03-11 2006-12-26 The Board Of Trustees Of The University Of Illinois Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
WO2003089450A2 (en) * 2002-04-22 2003-10-30 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
EP1572950B1 (de) 2002-06-17 2012-10-10 Thrasos, Inc. Einzeldomäne-tdf-verwandte verbindungen und analoge davon
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
EP2311980A1 (de) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
AU2003276903A1 (en) 2002-09-20 2004-05-04 Flowmedica, Inc. Method and apparatus for selective material delivery via an intra-renal catheter
US7063679B2 (en) * 2002-09-20 2006-06-20 Flowmedica, Inc. Intra-aortic renal delivery catheter
EP1585572A4 (de) 2002-09-20 2010-02-24 Flowmedica Inc Verfahren und vorrichtung zur intraaortalen wirkstoffabgabe an eine gefässverzweigung
EP1624909A2 (de) 2002-09-20 2006-02-15 FlowMedica, Inc. Gerät und verfahren zur einführung eines intraaortakalen katheters durch eine ablageschleuse
US7993325B2 (en) 2002-09-20 2011-08-09 Angio Dynamics, Inc. Renal infusion systems and methods
US6921371B2 (en) 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
US20050037011A1 (en) * 2002-11-21 2005-02-17 Jones Stephen N. Diagnosing and treating hematopoietic cancers
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
US7771372B2 (en) 2003-01-03 2010-08-10 Ekos Corporation Ultrasonic catheter with axial energy field
WO2004073504A2 (en) * 2003-02-20 2004-09-02 Proteon Therapeutics, Llc Methods for the treatment and prevention of diseases of biological conduits
US20050233342A1 (en) * 2003-03-07 2005-10-20 Muthiah Manoharan Methods of preventing off-target gene silencing
US20070179100A1 (en) * 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
EP2669377A3 (de) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modifizierte iRNA-Wirkstoffe
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
US8017762B2 (en) * 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP2353389B1 (de) * 2003-04-21 2015-11-04 Epeius Biotechnologies Corporation Zusammensetzungen zur Behandlung von Erkrankungen
EP1619995A2 (de) * 2003-04-22 2006-02-01 Ekos Corporation Ultraschallverstärkter zentralvenöser katheter
EP1635736A2 (de) 2003-06-05 2006-03-22 FlowMedica, Inc. Systeme und verfahren zur durchführung von bilateralen interventionen oder diagnose in verzweigten körperlumen
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US20060134287A1 (en) * 2003-08-20 2006-06-22 Vimini Robert J Packaging and cooking bag and method for packaging and preparing a meat product
DK1673457T3 (da) 2003-08-25 2011-09-05 Funzyme Biotechnologies Sa Nye svampeproteiner og nukleinsyrer, der koder for disse
US7291604B2 (en) * 2003-09-03 2007-11-06 The General Hospital Corporation Methods of treating restenosis
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
WO2005027980A1 (en) * 2003-09-12 2005-03-31 University Of Massachusetts Rna interference for the treatment of gain-of-function disorders
US20050059999A1 (en) * 2003-09-15 2005-03-17 Mongeon Luc R. Delivering genetic material to a stimulation site
WO2005034732A2 (en) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
DK1677735T3 (da) 2003-10-17 2014-10-27 Joslin Diabetes Center Inc Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
US20050125914A1 (en) * 2003-11-18 2005-06-16 Gerard Malle Hair shaping composition comprising at least one- non-hydroxide base
EP2260776A1 (de) 2003-11-21 2010-12-15 Vnus Medical Technologies, Inc. Gerät zum Behandeln der Halsschlagader
CA2487098A1 (en) * 2003-12-22 2005-06-22 F. Hoffmann-La Roche Ag Novel targets for obesity from fat tissue
CA2487107A1 (en) * 2003-12-22 2005-06-22 F. Hoffmann-La Roche Ag Novel targets for obesity from skeletal muscle
CA2554370A1 (en) * 2004-01-26 2005-08-25 Brett Premack Compositions and methods of use of w-peptides
US20070087986A1 (en) * 2004-01-26 2007-04-19 Brett Premack Compositions and methods for enhancing immunity by chemoattractant adjuvants
EP1713900A4 (de) * 2004-01-27 2009-06-17 Compugen Ltd Verfahren und systeme zur kommentierung biomolekularer sequenzen
WO2005091910A2 (en) 2004-03-04 2005-10-06 Flowmedica, Inc. Sheath for use in peripheral interventions
WO2005087217A1 (en) * 2004-03-05 2005-09-22 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
ES2423060T3 (es) * 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
GB0406728D0 (en) * 2004-03-25 2004-04-28 Hydrodynamic Gene Delivery Ltd Gene therapy
ATE418346T1 (de) * 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
AU2005233583B2 (en) * 2004-04-08 2011-02-03 Sangamo Therapeutics, Inc. Methods and compositions for modulating cardiac contractility
WO2005112980A2 (en) 2004-05-14 2005-12-01 Flowmedica, Inc. Bi-lateral local renal delivery for treating congestive heart failure and for bnp therapy
EP1789453A2 (de) * 2004-05-18 2007-05-30 Genentech, Inc. Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
EP1753458A4 (de) * 2004-05-19 2009-07-22 Wyeth Corp Modulation der immunglobulinproduktion und atopische erkrankungen
WO2006007375A2 (en) * 2004-06-16 2006-01-19 The General Hospital Corporation Use of bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
EP2789342A1 (de) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Verbindungen im Zusammenhang mit TDF und Analoga davon
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP1789070B1 (de) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in der neuronalen funktion
US20060051338A1 (en) 2004-08-20 2006-03-09 New York University Inhibition of mitogen-activated protein kinases in cardiovascular disease
US20100003241A1 (en) 2004-09-07 2010-01-07 Patrick Holt Agents for treatment or prevention of an allergic disorder
CA2580707C (en) 2004-09-24 2014-07-08 Alnylam Pharmaceuticals, Inc. Rnai modulation of apob and uses thereof
US20060069323A1 (en) * 2004-09-24 2006-03-30 Flowmedica, Inc. Systems and methods for bi-lateral guidewire cannulation of branched body lumens
EP2133081B1 (de) 2004-11-24 2012-01-04 Alnylam Pharmaceuticals Inc. RNAi-Modulation des BCR-ABL-Fusionsgens und dessen Verwendungen
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
BRPI0515819A (pt) * 2004-12-01 2008-08-05 Genzyme Corp métodos para o fornecimento direcionado de material genético ao fìgado
US20060154285A1 (en) * 2004-12-29 2006-07-13 Robishaw Janet D Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
BRPI0607306A2 (pt) 2005-01-25 2009-08-25 Prolexys Pharmaceuticals Inc derivados de quinoxalina como agentes anti-tumor
EP2236153A3 (de) 2005-01-25 2012-08-22 Five Prime Therapeutics, Inc. Zusammensetzungen und Methoden zur Behandlung von Herzkrankheiten
SG171690A1 (en) * 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis
CA2606084A1 (en) * 2005-06-17 2006-12-28 Abbott Laboratories Improved method of treating degenerative spinal disorders
DK3117833T3 (en) 2005-07-19 2019-03-18 Stemgen S P A Inhibition of Tumor-rich Potential of Tumor Stem Cells with LIF
WO2007014077A2 (en) * 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Rnai modulation of the rho-a gene and uses thereof
WO2007018318A1 (ja) * 2005-08-10 2007-02-15 National University Corporation Kanazawa University 小脳星状細胞及び／又は籠細胞特異的な遺伝子発現方法
EP2239328A3 (de) 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Verfahren und Zusammensetzungen zur Behandlung von neurologischen Erkrankungen
WO2007024589A2 (en) * 2005-08-24 2007-03-01 The Trustees Of Columbia University In The City Of New York Phagocyte enhancement therapy for atherosclerosis
TWI333959B (en) * 2005-08-31 2010-12-01 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
EP3031470A3 (de) 2005-09-09 2016-08-10 The Johns Hopkins University Manipulation der regulatorischen t-zell- und dc-funktion durch targeting des neuritin-gens mit antikörpern, agonisten und antagonisten
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
EP1937311A2 (de) 2005-09-30 2008-07-02 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Verfahren und zusammensetzungen zur modulierung der immuntoleranz
US20070100323A1 (en) * 2005-10-31 2007-05-03 Ludwig Florian N Facilitation of endothelialization by in situ surface modification
EP2202239A1 (de) 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAi-Hemmung von Influenza-Virus-Neubildungen
AU2006311725B2 (en) * 2005-11-04 2011-11-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of NAV1.8 gene
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
PL1969003T3 (pl) 2005-12-14 2011-05-31 Herantis Pharma Plc Zastosowanie białka czynnika neurotroficznego
US8172792B2 (en) * 2005-12-27 2012-05-08 Tyco Healthcare Group Lp Embolic protection systems for bifurcated conduits
WO2007132355A2 (en) 2006-01-26 2007-11-22 Recopharma Ab Compositions and methods for inhibiting viral adhesion
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
EP1818395A1 (de) 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
JP2009525757A (ja) 2006-02-10 2009-07-16 ザ ユニバーシティ オブ シンシナティ 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１
WO2008091349A1 (en) * 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
US20090221072A1 (en) * 2006-02-15 2009-09-03 Chen Thomas T Compositions and methods for modulating cell differentiation
US20070225750A1 (en) * 2006-03-10 2007-09-27 Brooke Ren Embolic protection systems
JP5704741B2 (ja) 2006-03-31 2015-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇ５遺伝子発現の抑制のための組成物および方法
EP2343551B1 (de) 2006-04-10 2014-05-28 Genentech, Inc. Dishevelled PDZ-Modulatoren
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
WO2007130429A2 (en) * 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US20090304704A1 (en) 2006-05-03 2009-12-10 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash)
US7605251B2 (en) 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
EP2392583A1 (de) 2006-05-19 2011-12-07 Alnylam Europe AG. RNAi-Modulation von AHA und therapeutische Verwendungen davon
US7888498B2 (en) * 2006-05-22 2011-02-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
US8383597B2 (en) * 2006-05-25 2013-02-26 Cornell Research Foundation, Inc. G proteins in tumor growth and angiogenesis
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US8153369B2 (en) 2006-06-05 2012-04-10 Cancer Care Ontario Assessment of risk for colorectal cancer
US7771401B2 (en) 2006-06-08 2010-08-10 Angiodynamics, Inc. Selective renal cannulation and infusion systems and methods
JP5250548B2 (ja) 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体ｈ因子の標的化
WO2008054561A2 (en) 2006-07-11 2008-05-08 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
US20080021063A1 (en) * 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US8153803B2 (en) * 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US7943310B2 (en) * 2006-08-30 2011-05-17 Centocor Ortho Biotech Inc. Methods for assessing response to therapy in subjects having ulcerative colitis
WO2008032210A2 (en) 2006-09-14 2008-03-20 Institut Pasteur Methods of using sip-10 to assess hcv clearance and/or response to interferon therapy
CN105061580B (zh) 2006-10-03 2020-06-05 罗格斯新泽西州立大学 多肽和药物组合物及其应用
US8192363B2 (en) 2006-10-27 2012-06-05 Ekos Corporation Catheter with multiple ultrasound radiating members
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
PL3225251T3 (pl) 2006-12-21 2020-06-29 H. Lundbeck A/S Modulacja aktywności proneurotrofin
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
EP2423220B1 (de) 2007-01-30 2015-04-29 Epivax, Inc. Regulatorische t-zellen-epitope sowie zusammensetzungen damit und anwendungen davon
WO2008103336A1 (en) * 2007-02-21 2008-08-28 Cook Incorporated Methods for intravascular engraftment in heart
AU2008222563A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
CA2684321A1 (en) 2007-03-21 2008-09-25 Effat Emamian Compositions comprising pkac fragments and uses thereof for inhibiting akt1, p70s6k or abl activity
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
ES2471118T3 (es) 2007-06-22 2014-06-25 Ekos Corporation Método y aparato para el tratamiento de hemorragias intracraneales
EP2319926B1 (de) 2007-07-05 2016-08-31 Arrowhead Research Corporation DSRNA zur Behandlung viraler Infektionen
US8858490B2 (en) 2007-07-18 2014-10-14 Silk Road Medical, Inc. Systems and methods for treating a carotid artery
JP5290290B2 (ja) 2007-07-18 2013-09-18 シルク・ロード・メディカル・インコーポレイテッド 頚動脈血流の逆流を確立する方法およびシステム
US20090198172A1 (en) * 2008-02-05 2009-08-06 Garrison Michi E Interventional sheath with retention features
EP2229186A2 (de) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Kohlenhydrat-konjugate als mittel zur abgabe von oligonukleotiden
WO2009076400A2 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
US20090176729A1 (en) * 2007-12-14 2009-07-09 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP3789069B1 (de) 2008-02-05 2024-04-03 Silk Road Medical, Inc. Interventionelles kathetersystem und verfahren
EP2244740A1 (de) 2008-02-19 2010-11-03 Celladon Corporation Zusammensetzungen zur verbesserten aufnahme von virusvektoren in das myokard
CN105267233B (zh) 2008-03-05 2019-07-26 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的组合物和方法
US8575123B2 (en) 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US20090274696A1 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
WO2009136297A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting toxin a from clostridium difficile
WO2009136298A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
CA2726804C (en) 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
KR20110017005A (ko) * 2008-07-15 2011-02-18 에프. 호프만-라 로슈 아게 Ｔｇｆ-베타 수용체 유전자 발현 억제용 조성물 및 방법
EP2321264B1 (de) * 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylaseinhibitoren und anwendungen davon
US8574245B2 (en) 2008-08-13 2013-11-05 Silk Road Medical, Inc. Suture delivery device
AU2009285644B2 (en) 2008-08-29 2015-08-20 Janssen Biotech, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
EP2690175B1 (de) 2008-09-02 2016-12-28 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
US8546554B2 (en) 2008-09-25 2013-10-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
US9207242B2 (en) 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
EP2937418B1 (de) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der Expression des Transthyretin
WO2010054195A2 (en) 2008-11-07 2010-05-14 Centocor Ortho Biotech Inc. Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
EP2373382B1 (de) 2008-12-10 2017-02-15 Alnylam Pharmaceuticals, Inc. Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
CN102307996A (zh) 2009-02-03 2012-01-04 弗·哈夫曼-拉罗切有限公司 用于抑制ptp1b基因表达的组合物和方法
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
WO2010110931A2 (en) 2009-03-23 2010-09-30 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
US9675673B2 (en) * 2009-04-24 2017-06-13 Ingeneron Incorporated Transluminal delivery of oncoltyic viruses for cancer therapy
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
JP2012526533A (ja) * 2009-05-15 2012-11-01 エフ．ホフマン−ラ ロシュ アーゲー グルココルチコイドレセプター（ｇｃｒ）遺伝子の発現を阻害するための組成物及び方法
WO2010141752A1 (en) 2009-06-03 2010-12-09 Silk Road Medical, Inc. System and methods for controlling retrograde carotid arterial blood flow
EP4218794A3 (de) 2009-06-10 2023-09-13 New York University Immunologisches targeting pathologischer tau-proteine
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
US20110112176A1 (en) 2009-11-09 2011-05-12 John Frederick Boylan Compositions and methods for inhibiting expression of kif10 genes
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
US20110196016A1 (en) * 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US20130281510A1 (en) 2010-03-29 2013-10-24 Kumamoto University siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
EP2377888A1 (de) 2010-04-07 2011-10-19 Corimmun GmbH Fusionsprotein
US11020444B2 (en) * 2010-04-23 2021-06-01 Scicotec Gmbh Transluminal delivery of viruses for treatment of diseased tissue
US9586044B2 (en) 2010-04-28 2017-03-07 Kimberly-Clark Worldwide, Inc. Method for increasing the permeability of an epithelial barrier
EP2563450B1 (de) 2010-04-28 2017-07-26 Kimberly-Clark Worldwide, Inc. Vorrichtung zur verabreichung eines medikaments gegen rheumatoide arthritis
WO2011135531A2 (en) * 2010-04-28 2011-11-03 Kimberly-Clark Worldwide, Inc. MEDICAL DEVICES FOR DELIVERY OF siRNA
CN102958556B (zh) 2010-04-28 2017-02-15 金伯利-克拉克环球有限公司 细胞相互作用增强的纳米图案化医疗装置
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US20120076736A1 (en) * 2010-09-17 2012-03-29 Rochester Institute Of Technology Host supported genetic biosensors
CN103391784A (zh) 2010-10-15 2013-11-13 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
EP3434772A3 (de) 2010-10-18 2019-03-20 Arrowhead Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
PT2635299T (pt) 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
GB2485385A (en) 2010-11-12 2012-05-16 Univ Manchester Trimeric fusion protein comprising collagen and a prokaryotic/ viral trimerisation domain
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
EP2698635A3 (de) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Verfahren und Zusammensetzungen zum Targeting auf Stellen neovaskulären Wachstums
EP3026432A3 (de) 2010-12-27 2016-07-27 Brown University Verfahren zur vorhersage der patientenreaktion auf eine behandlung mit biglycan
US11458290B2 (en) 2011-05-11 2022-10-04 Ekos Corporation Ultrasound system
US9592398B2 (en) 2011-05-12 2017-03-14 Medtronic, Inc. Leadless implantable medical device with osmotic pump
EP2723756B1 (de) 2011-06-21 2020-03-11 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression von apolipoprotein-c-iii (apoc3)-genen
EP2723351B1 (de) 2011-06-21 2018-02-14 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
PT2726613T (pt) 2011-06-30 2018-10-26 Arrowhead Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes do vírus da hepatite b
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
MX355128B (es) 2011-10-14 2018-04-06 Genentech Inc Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
US9796974B2 (en) 2011-11-18 2017-10-24 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
SG10201604810UA (en) * 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2013152230A1 (en) 2012-04-04 2013-10-10 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
EP2854923B1 (de) 2012-06-05 2019-08-21 Muffin Incorporated Kathetersysteme und verfahren zur zelltherapie
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
EP2877214B1 (de) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Prognose von mit diabetes assoziierten komplikationen
EP3613765B1 (de) 2012-08-03 2024-10-02 Dana-Farber Cancer Institute, Inc. Antikörper gegen das abstossende wegweisermolekül b (rgmb)
AU2013296321B2 (en) 2012-08-03 2019-05-16 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US9340787B2 (en) 2012-11-15 2016-05-17 Yale University Compositions and methods of using micro RNAs
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
WO2014128257A1 (en) 2013-02-22 2014-08-28 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
SI2968461T1 (sl) 2013-03-13 2023-01-31 Genzyme Corporation Fuzijski proteini, ki vsebujejo vezavna dela PDGF in VEGF in postopek njihove uporabe
WO2014151734A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9822418B2 (en) 2013-04-22 2017-11-21 Icahn School Of Medicine At Mount Sinai Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
BR112015027336A2 (pt) 2013-05-01 2017-09-26 Genzyme Corp composições e processos para tratamento de atrofia muscular espinhal
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
KR102181336B1 (ko) 2013-06-13 2020-11-24 오르제네시스 엘티디. 세포 집단, 이의 전환분화 방법 및 이용 방법
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
EP3030171B1 (de) 2013-08-08 2017-11-01 Global Bio Therapeutics, Inc. Injektionsvorrichtung für minimal invasive eingriffe
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
WO2015081290A1 (en) 2013-11-27 2015-06-04 Inis Biotech Llc Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2015106128A2 (en) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
EP3134546A4 (de) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumorsuppressor und onkogene biomarker zur vorhersage der anti-immun-checkpoint-inhibitorreaktion
US20170190762A1 (en) 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
US20170246259A1 (en) 2014-09-10 2017-08-31 Georgetown University Compositions and Methods of Using Interleukin-4 Induced Gene 1 (IL-4I1)
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
US10092742B2 (en) 2014-09-22 2018-10-09 Ekos Corporation Catheter system
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
US11236139B2 (en) 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
EP3925979A3 (de) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusionsproteine und verfahren dafür
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3256608A4 (de) 2015-02-13 2019-02-20 Icahn School of Medicine at Mount Sinai Rna-haltige zusammensetzungen und verfahren zu deren verwendung
US10487324B2 (en) 2015-02-25 2019-11-26 Washington University Methods to detect motor neuron disease comprising micro-RNAs
HK1248812A1 (zh) 2015-03-06 2018-10-19 Dana-Farber Cancer Institute, Inc. 预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记
WO2016144917A1 (en) 2015-03-10 2016-09-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
EP3929293A3 (de) 2015-04-03 2022-03-16 University Of Massachusetts Vollständig stabilisierte asymmetrische sirna
RS60762B1 (sr) 2015-04-03 2020-10-30 Univ Massachusetts Oligonukleotidna jedinjenja za ciljane irnk hantingtina
WO2016161378A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EP3280451B8 (de) 2015-04-08 2019-09-25 The United States of America, as represented by the Secretary, Department of Health and Human Services Virale gentherapie zur behandlung von cholesterinspeicherungserkrankung oder -störung
EP3291799A1 (de) 2015-05-05 2018-03-14 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Kationische nukleinsäurepolymerzusammensetzungen und verfahren zur herstellung und verwendung davon
US20180140626A1 (en) 2015-05-14 2018-05-24 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
CN107708581B (zh) 2015-06-10 2021-11-19 Ekos公司 超声波导管
EP3722314A1 (de) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
HRP20231163T1 (hr) 2015-07-31 2024-03-15 The Johns Hopkins University Prolijekovi glutaminskih analoga
WO2017023793A2 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CN115957337A (zh) 2015-08-07 2023-04-14 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
EP3347486A4 (de) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York Reduktion von er-mam-lokalisierten app-c99 und verfahren zur behandlung der alzheimer-krankheit
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
EP3368157B1 (de) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
MX381665B (es) 2016-01-13 2025-03-13 Genzyme Corp Star Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos.
WO2017132669A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
JP2019512271A (ja) 2016-03-21 2019-05-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
CA2932910A1 (en) 2016-06-14 2017-12-14 Entos Pharmaceuticals Inc. Methods for diagnosing and treating metastatic cancer
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
CA3034643A1 (en) 2016-09-20 2018-03-29 Ellen Weisberg Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
EP3526248A4 (de) 2016-10-17 2020-07-08 Musc Foundation for Research Development Zusammensetzungen und verfahren zur behandlung von läsionen des zentralnervensystems
WO2018085836A1 (en) 2016-11-07 2018-05-11 Colorado State University Research Foundation Anti-hiv peptides
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
EP3609577B1 (de) 2017-04-14 2024-09-11 University of Massachusetts Braune fettselektive adipokine
WO2018207179A1 (en) 2017-05-08 2018-11-15 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof
WO2018226685A2 (en) 2017-06-06 2018-12-13 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
CA3068010A1 (en) 2017-06-20 2018-12-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
WO2018237245A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
CA3070468A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
EP3460057A1 (de) 2017-09-22 2019-03-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Kdac varianten und deren nutzung
JP7274472B2 (ja) 2017-10-05 2023-05-16 エピバックス、インコーポレイテッド 制御性ｔ細胞エピトープ
JP7348185B2 (ja) 2017-12-21 2023-09-20 アルニラム ファーマスーティカルズ インコーポレイテッド キラル富化二本鎖ｒｎａ剤
EP3759125A4 (de) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-btnl2 und immuncheckpoint-blockierungsreagenzien
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
MX2020010094A (es) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
EP3790893A4 (de) 2018-05-11 2022-03-16 University Of Massachusetts Verfahren zur verbesserung der leptinempfindlichkeit zur behandlung von fettleibigkeit und diabetes
CA3098320A1 (en) 2018-05-16 2019-11-21 The General Hospital Corporation Methods of modulating antigenicity to enhance recognition by t-cells
AU2019272848A1 (en) 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
WO2019229264A1 (en) 2018-06-01 2019-12-05 Sanofi Combination therapy for treating hepatitis b virus infection
US12303549B2 (en) 2018-06-21 2025-05-20 University Of Rochester Methods of treating or inhibiting onset of Huntington's disease
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
EP3626820A1 (de) 2018-09-20 2020-03-25 Fundación Imdea Nanociencia Krebsbekämpfende zusammensetzungen mit mirna-imitatoren und verwendungen davon
AU2019366366B2 (en) 2018-10-22 2025-09-25 William D. Carlson Therapeutic combinations of TDFRPs and additional agents and methods of use
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
US20220056444A1 (en) 2018-12-05 2022-02-24 Empirico Inc. Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
EP3911632A1 (de) 2019-01-15 2021-11-24 Empirico Inc. Prodrugs von alox-15-inhibitoren und verfahren zur verwendung davon
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
EP3923962A2 (de) 2019-02-13 2021-12-22 University of Rochester Gennetzwerke, die die remyelinisierung des menschlichen gehirns vermitteln
EP3941938A1 (de) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. Für das b-zell-reifungsantigen spezifische t-zell-rezeptoren zur behandlung von krebs
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
WO2020205473A1 (en) 2019-03-29 2020-10-08 Decerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP3966328A4 (de) 2019-05-06 2023-10-18 University Of Massachusetts Anti-c9orf72-oligonukleotide und zugehörige verfahren
CA3141712A1 (en) 2019-05-24 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
AU2020393917A1 (en) 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
BR112022010425A2 (pt) 2019-12-03 2022-08-23 Evotec Int Gmbh Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
AR117715A1 (es) 2019-12-17 2021-08-25 Univ Nacional Del Litoral Unl Interferón hiperglicosilado con inmunogenicidad reducida
US12037585B2 (en) 2019-12-23 2024-07-16 University Of Massachusetts Oligonucleotides for tissue specific gene expression modulation
WO2021141733A1 (en) 2020-01-07 2021-07-15 The Procter & Gamble Company Method of modulating a fibrotic condition
WO2021150925A1 (en) 2020-01-24 2021-07-29 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
EP4110913A4 (de) 2020-02-28 2024-07-24 University of Massachusetts Oligonukleotide zur prnp-modulation
AU2021244600A1 (en) 2020-03-26 2022-11-03 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability
US12344839B2 (en) 2020-03-27 2025-07-01 University Of Massachusetts Dual-acting siRNA based modulation of C9orf72
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
EP4158028A4 (de) 2020-05-28 2024-10-02 University Of Massachusetts Oligonukleotide zur sars-cov-2-modulation
EP4182458A2 (de) 2020-07-20 2023-05-24 Dana-Farber Cancer Institute, Inc. Verfahren und zusammensetzungen zur behandlung und prävention von coronavirusinfektionen
WO2022020548A2 (en) 2020-07-23 2022-01-27 President And Fellows Of Harvard College Variant txnip compositions and methods of use thereof for the treatment of degenerative ocular diseases
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス， インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
WO2022072820A1 (en) 2020-10-02 2022-04-07 Dracen Pharmaceuticals, Inc. Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof
US12006550B2 (en) 2020-10-12 2024-06-11 University Of South Carolina Targeting treatment for ADAM30 in pathological cells
EP4343004A3 (de) 2020-10-19 2024-09-11 Dana-Farber Cancer Institute, Inc. Keimbahnbiomarker einer klinischen reaktion und nutzen für eine immuncheckpoint-inhibitortherapie
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
WO2022173932A1 (en) 2021-02-11 2022-08-18 Dana-Farber Cancer Institute, Inc. Methods of treating cancers using sting agonists
KR20230165212A (ko) 2021-03-02 2023-12-05 다나-파버 캔서 인스티튜트 인크. 적혈구 장애의 치료 방법
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
CA3220925A1 (en) 2021-06-09 2022-12-15 Kara Carter Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
WO2023280988A1 (en) 2021-07-09 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving relaxation of striated myocytes
CA3236365A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
WO2023081908A2 (en) 2021-11-08 2023-05-11 University Of Massachusetts Oligonucleotides for sod1 modulation
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
CA3249166A1 (en) 2022-02-16 2023-08-24 The Johns Hopkins University METHODS FOR REDUCING PATHOLOGICAL ALPHA-SYNUCLEIN USING AGENTS THAT MODULATE FNDC5 OR BIOLOGICALLY ACTIVE FRAGMENTS THEREIN
US20250302493A1 (en) * 2022-05-10 2025-10-02 Shifamed Holdings, Llc Thrombus removal systems and associated methods
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
EP4658294A2 (de) 2023-02-02 2025-12-10 University of Rochester Kompetitiver ersatz von gliazellen
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
CN118001292B (zh) 2023-09-01 2024-11-29 香港中文大学（深圳） 靶向rna的组合物及其用途
WO2026117631A2 (en) 2024-11-26 2026-06-04 City Therapeutics, Inc. Factor xi rnai agent compositions and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
US4332893A (en) * 1980-06-13 1982-06-01 Rosenberg Ralph A Process for the production of an insulin-producing cell line of pancreatic beta cells
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
EP0273085A1 (de) * 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
DE3742049A1 (de) * 1987-12-11 1989-06-22 Theurer Karl Eugen Herstellung und anwendung von impfstoffen und diagnostika fuer virus- und krebserkrankungen
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990011734A1 (en) * 1989-03-31 1990-10-18 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5049132A (en) * 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US7331366B1 (en) 2005-05-31 2008-02-19 Patterson Brian A Money and card holding assembly

Also Published As

Publication number Publication date
JPH06509328A (ja) 1994-10-20
JP3712409B2 (ja) 2005-11-02
ATE214576T1 (de) 2002-04-15
DE69232497D1 (de) 2002-04-25
EP1927368A2 (de) 2008-06-04
EP1013287A2 (de) 2000-06-28
JP2002239010A (ja) 2002-08-27
EP1213032A1 (de) 2002-06-12
EP1013287A3 (de) 2000-07-05
WO1993000051A1 (en) 1993-01-07
JP2001213806A (ja) 2001-08-07
EP0591385B1 (de) 2002-03-20
ES2301602T3 (es) 2008-07-01
US5328470A (en) 1994-07-12
EP1927368A3 (de) 2008-06-11
DK0591385T3 (da) 2002-06-24
DE69232497T2 (de) 2002-11-14
DE1213032T1 (de) 2003-02-06
EP0591385A1 (de) 1994-04-13
EP0591385A4 (en) 1996-11-27
EP1213032B1 (de) 2008-02-13
CA2112376A1 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
ATE214576T1 (de) Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür
DE69735496D1 (de) Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Genen involviert
Bertsch et al. Effect of mechanical stimulation on cell proliferation in mouse epidermis and on growth regulation by endogenous factors (chalones)
Christ et al. The application of gene therapy to the treatment of erectile dysfunction.
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE69331144D1 (de) Entwicklung eines vektors zur erreichung von genexpression in der epidermis transgener tiere
ATE225852T1 (de) Menschlicher epidermaler gen-promotor
Papp et al. Pancreaticoduodenal lymph flow and lipase activity in acute experimental pancreatitis
CN105944243A (zh) 一种eNOS表达与活化的调控装置及周围动脉疾病的治疗装置
ATE80307T1 (de) Verbesserungen im gebrauch oder in bezug auf den gebrauch von egf.
JPH0471894B2 (de)
Antoniades Hypoglycaemic effect of adipose-tissue extracts in adrenalectomised rats
Penninger et al. Recent progress in the field of artificial organs
RU2006068C1 (ru) Способ моделирования миокардита
CN118526514A (zh) 一种促进缺血性脑卒中后血管新生的核酸药物及其应用
SU1613956A1 (ru) Средство дл модул ции функциональной активности естественных киллеров IN VIтRо
Korepanov STATE OF THE ART 0F LASER THERAPY IN RUSSIA: A BRIEF OVERVIEW
RU1780741C (ru) Способ лечени деформирующего остеоартроза
Gold et al. Experimental pyelonephritis in dogs
Marx The 23-million-dollar quest pays off
Africa An Act (No. 65 of 1983) to provide for the donation or the making available of human bodies and tissue for the purposes of medical or dental training, research or therapy or the advancement of medicine or dentistry in general; for the post-mortem examination of certain human bodies; for the removal of tissue, blood and gametes from the bodies of living persons and the use thereof for medical or dental purposes; for the control of the artificial insemination of persons; and for the regulation of the import and export of human tissue, blood and gametes; and to provide for matters connected therewith. Date of commencement: 12 July 1985 (the Human Tissue Act, 1983)
Delano A Study in the Internal Therapeutics of Radium
Barnes Inter-Atrial Septal Defect in Mother and Son
Chester-street Foreign Department.
CN112843084A (zh) MiR-122-5p在制备促进创伤愈合药物中的应用

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties